Evidence map›Paper›PMID 31394872›Full record

ArticleJournal of clinical medicine2019

Detection of

Begona Jimenez Rodriguez, Gema Diaz Córdoba, Alicia Garrido Aranda, Martina Álvarez, Luis Vicioso, Casilda Llácer Pérez, Cristina Hernando, Begoña Bermejo, Ana Julve Parreño, Ana Lluch and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Guideline
  2. Detection ofBiomolecules · 2021
    Trial
  3. Review
  4. Review
  5. Review of ctDNA in breast cancer - present utility and future perspectives.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Personalized treatment approach for HER2-positive metastatic breast cancer.Medical oncology (Northwood, London, England) · 2024
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Begona Jimenez RodriguezUnidad de Gestión Clínica Intercentros de Oncología Medica, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, 29010 Málaga, Spain.
Gema Diaz CórdobaRadiology Department, Hospital Clínico Universitario Virgen de la Victoria de Málaga, 29010 Málaga, Spain.
Alicia Garrido ArandaInstituto de Investigación Biomédica de Málaga (IBIMA)-CIMES-UMA, 29010 Málaga, Spain.
Martina ÁlvarezInstituto de Investigación Biomédica de Málaga (IBIMA)-CIMES-UMA, 29010 Málaga, Spain.
Luis ViciosoHistopathology Department, Hospital Clínico Universitario Virgen de la Victoria de Málaga, 29010 Málaga, Spain.
Casilda Llácer PérezUnidad de Gestión Clínica Intercentros de Oncología Medica, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, 29010 Málaga, Spain.
Cristina HernandoHospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain.
Begoña BermejoHospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain.
Ana Julve ParreñoHospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, 46010 Valencia, Spain.
Ana LluchCentro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029 Madrid, Spain.
Matthew B RyderSysmex Inostics, GmbH, 20251 Hamburg, Germany.
Frederick S JonesSysmex Inostics, GmbH, 20251 Hamburg, Germany.
Johannes FredebohmSysmex Inostics, GmbH, 20251 Hamburg, Germany.
Frank HoltrupSysmex Inostics, GmbH, 20251 Hamburg, Germany.
María Isabel Queipo-OrtuñoUnidad de Gestión Clínica Intercentros de Oncología Medica, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, 29010 Málaga, Spain. maribelqo@gmail.com.
Emilio AlbaUnidad de Gestión Clínica Intercentros de Oncología Medica, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, 29010 Málaga, Spain.
Hospital Clínico Universitario Virgen de la Victoria · ESSysmex (Germany) · DEINCLIVA Health Research Institute · ESInstituto de Investigación Biomédica de Málaga · ESUniversitat de València · ES

Funding

Consejería de Salud. Junta de Andalucía Nicolas Monardes, C-0030-2018Instituto de Salud Carlos III Miguel Servet Type II, CPI13/00003
6 · The paper itself

Abstract

Circulating tumor DNA (ctDNA) has emerged as a non-invasive "liquid biopsy" for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer after mammography findings, comparing

Indexed as

breast cancercirculating tumor DNA (ctDNA)early-stage cancerliquid biopsymolecular profiling

Identifiers

PMID31394872
PMCPMC6723048
OpenAlexW2966618931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.